Drugs / SEVIPROTIMUT-L
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01546571 | May 2012 → Apr 2021 | melanoma | Polynoma LLC | Terminated | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SEVIPROTIMUT-L | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137341 ↗ |
| Known as | POL-103A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01546571 ↗ |
| Route | Other | “POL-103A is administered intradermally” NCT01546571 ↗ |